Medtronic has presented data on EffectivCRT for heart failure patients with atrial fibrillation (AF) at the 2016 European Society of Cardiology (ESC) Congress in Rome, Italy.
The Cardiac Resynchronization Therapy Efficacy Enhancement (CRTee) study demonstrated that the Medtronic-exclusive device-based EffectivCRT(TM) during AF algorithm enhances therapy delivery in heart failure patients with AF.
Medtronic claims that its new product EffectivCRT during AF feature can automatically identify the effectiveness of the left ventricular pace and adjusts pacing rates during AF.
It is important for heart failure patients with AF, because the company says that the pacing pulse from the device has a possibility to be ineffective or interrupted due to irregular heart rhythm.
The EffectivCRT Diagnostic and EffectivCRT during AF are available on Claire MRI Quad CRT-D SureScan in Europe.
The EffectivCRT features are for investigational study in the US and the Claria CRT-D is not approved for sale in the US.
Claria device has been approved for full-body MRI scans in 1.5 and 3T machines and it can be paired with Attain Performa quadripolar lead technology.
Apart from the new EffectivCRT features, Claria device is equipped with AdaptivCRT algorithm, which can provide up to 46% reduction in AF risk and can reduce the odds of 30 day heart failure readmission for patients by as much as 59%.
CRTee was conducted on 71 patients with paroxysmal, persistent or permanent AF. 66 patients were first randomised to an existing algorithm or the new EffectivCRT algorithm, with an outcome of higher percent effective CRT to be delivered during AF.
The study showed the EffectivCRT group exhibited increased effective pacing during AF by 7% from 81% to 88% and heart rates increasing by 3 beats per minute.
Medtronic Cardiac Rhythm and Heart Failure division medical director and Heart Failure business vice president and general manager David Steinhaus said: "Medtronic has made great strides in providing patients with a range of products that incorporate the most advanced technology available to improve CRT response.
"We are continually expanding our research and development to create better solutions for improved outcomes, based on individualized care in cardiac rhythm and heart failure devices."